Polynucleotides for facial skin rejuvenation comparing between sharp and cannula techniques

A comparative study between needle versus cannula technique of polynucleotide injection for facial skin quality

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240716010

Enrollment

Registered

2024-07-16

Start date

2023-12-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To study the effectiveness of polynucleotides on the cheek area To assess the side effects and safety between the sharp needle and blunt cannula injection techniques. Polynucleotides, facial pores, pore size, skin quality

Interventions

Participant faces were divided into two sides using block randomization, with Cheek A receiving 1 ml of polynucleotide via a 31G needle and Cheek B via a 25G cannula. A topical anesthesia was applied

Experimental Drug

Polynucleotides injection by sharp and cannula techniques

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 to 50 years 2.In good health with no serious chronic illnesses 3.Has enlarged pores on both cheeks equally 4.Able to attend scheduled appointments and comply with the research protocol 5.Willing to participate in the research by signing the consent form

Exclusion criteria

Exclusion criteria: History or suspicion of infection at the lesion site Uncontrolled inflammatory acne vulgaris History of keloid scars or hypertrophic scars Immunocompromised condition History of skin cancer History of herpes infection History of taking vitamin A derivatives in the past 3 months History of receiving treatment on the cheeks with laser, dermabrasion, chemical peeling, radiofrequency, or focused ultrasound in the past 3 months Injection of fillers in the cheek area within the past 6 months History of diabetes History of connective tissue disorders History of allergy to anesthetics Pregnant or breastfeeding women Refusal or request to withdraw from the study

Design outcomes

Primary

Measure	Time frame
Pore volume week 0, 4, 8, 12, 16, and 20 Antera 3D, Visia skin analysis, Criteria of visual assessment for pore	—

Secondary

Measure	Time frame
Side effects week 0, 4, 8, 12, 16, and 20 Subjective evaluation,Sebum level week 0, 4, 8, 12, 16, and 20 Sebumeter,Moisture week 0, 4, 8, 12, 16, and 20 MoistureMeter by Delfin,Skin roughness week 0, 4, 8, 12, 16, and 20 Antera 3D, Visia skin analysis	—

Countries

Thailand

Contacts

Public ContactPanod Chinpipat

Faculty of Medicine Ramathibodi Hospital, Mahidol university

panod.chin@gmail.com66859671997

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026